STOCK TITAN
  1. Home
  2. News
  3. IKT

Inhibikase Therapeutics Inc - IKT STOCK NEWS

Welcome to our dedicated news page for Inhibikase Therapeutics (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inhibikase Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inhibikase Therapeutics's position in the market.

News
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Rhea-AI Summary
Inhibikase Therapeutics provided a shareholder update, highlighting progress on their 201 Trial for Parkinson's disease. The company is in the process of enrolling the last patient for the trial and has had positive interactions with the FDA regarding their IkT-001Pro development. They are planning Phase 3 protocols and exploring new indications for their therapies. Additionally, they are seeking grant support for biomarker research and considering IkT-001Pro for Pulmonary Arterial Hypertension. Overall, the company is focused on advancing their pipeline and bringing innovative treatments to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Rhea-AI Summary
Inhibikase Therapeutics, Inc. plans to discuss IkT-001Pro as a potential treatment for Pulmonary Arterial Hypertension with the FDA. The company aims to modify the course of PAH, a rare disease affecting the pulmonary microvasculature. Previous research suggests that IkT-001Pro may offer a safer and better-tolerated therapeutic option compared to existing treatments. The global PAH market size was $7.66 billion in 2023, with an estimated growth rate of 5.4% from 2024 to 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Rhea-AI Summary
Inhibikase Therapeutics, Inc. reports financial results for Q4 and full year 2023, highlighting recent developments such as the completion of a pre-NDA meeting with the FDA for IkT-001Pro and active enrollment in the Phase 2 201 Trial of Risvodetinib for Parkinson's disease. The company also published Phase 1 results of Risvodetinib in the Journal of Parkinson's Disease. Financially, the company reported a net loss of $19.0 million for 2023, with R&D expenses of $13.6 million and SG&A expenses of $6.7 million. Cash, cash equivalents, and marketable securities were $13.3 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.09%
Tags
earnings
News
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announces Dr. Milton Werner's presentation on the 201 Trial evaluating risvodetinib for Parkinson's disease at the 2024 AD/PD Meeting. The trial aims to modify the course of Parkinson's disease and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
News
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) plans to pursue eleven indications for IkT-001Pro, a prodrug of imatinib mesylate, after positive outcomes from discussions with the FDA. The Company is confident in the NDA development process and aims to modify the course of Parkinson's disease and related disorders. The FDA's feedback indicates potential flexibility in dosage forms for IkT-001Pro, opening opportunities for broader applications beyond blood and stomach cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
News
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) has announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and the company plans to seek all 11 indications for which imatinib mesylate has been approved. In addition, the company continues to make progress in its evaluation of risvodetinib in the 201 Trial in Untreated Parkinson’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags
none
News
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) published Phase 1 clinical studies demonstrating the safety and tolerability of risvodetinib, a potential disease-modifying therapy for Parkinson’s disease. The drug was well tolerated by healthy volunteers and patients with Parkinson’s disease, with no serious adverse events reported. The company is advancing its Phase 2 201 Trial, with topline results expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
clinical trial
-
News
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Rhea-AI Summary
Inhibikase Therapeutics, Inc. announced the retirement of Chief Financial Officer Joseph Frattaroli at the end of the first quarter of 2024. Garth Lees-Rolfe, the Vice-President for Finance, will be promoted to Chief Financial Officer. The company expressed gratitude to Joe for his years of service and highlighted the successful transition into a public company under his leadership. Dr. Milton Werner, President and CEO, commended Joe's contributions and expressed confidence in Garth's ability to drive the company's growth as the new CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
News
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) has experienced a 68% increase in stock price since October 9, 2023. The company has made significant progress in its neurodegenerative and cancer therapeutics programs, including advancing clinical trials for Parkinson's disease and Multiple System Atrophy. They have also developed technologies to improve drug absorption and have made significant strides in the commercialization of their therapeutics. The company is optimistic about transformative treatments in neurodegeneration and is looking forward to a successful 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
News
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that the FDA has granted a pre-NDA meeting to discuss the requirements for approval of IkT-001Pro, a protein kinase inhibitor therapeutic for blood and stomach cancers. The 501 bioequivalence study demonstrated minimal adverse events and identified bioequivalent doses of IkT-001Pro to 400 mg and 600 mg imatinib mesylate. The company intends to submit an NDA for up to 8 indications in adults with blood or stomach cancers, similar to the adult indications for imatinib mesylate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
none
Stock IKT logo
Inhibikase Therapeutics Inc

Nasdaq:IKT

IKT Rankings

#5266 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IKT Stock Data

14.38M
5.57M
13.85%
9.58%
0.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Atlanta

About IKT

inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.